Results 121 to 130 of about 213,637 (257)

Clinical trials and progress with paclitaxel in ovarian cancer

, 2010
Sanjeev Kumar1, Haider Mahdi2, Christopher Bryant1, Jay P Shah1, Gunjal Garg3, Adnan Munkarah41Department of Obstetrics and Gynecology, Wayne State University School of Medicine and Karmanos Cancer Institute Detroit, Michigan; 2Department of Obstetrics ...
Sanjeev Kumar, Haider Mahdi, et al, Christopher Bryant   +3 more
core  

Tailoring drug‐to‐lipid ratio in redox‐responsive lipid‐mimetic prodrug liposomes for superior cabazitaxel delivery and antitumor efficacy

BMEMat, EarlyView.
Redox‐responsive lipid‐mimetic prodrug liposomes with high drug‐to‐lipid ratios enhance cabazitaxel delivery, prolong circulation, and enable tumor‐selective drug release for superior antitumor efficacy and safety. Abstract Liposomes represent one of the most extensively investigated nanocarriers in drug delivery.
Shengyao Xu, Danping Wang, Si Zheng, Zhiyu Kuang, Ya Gao, Haiyu Zhao, Lurong Zhang, Jiayu Guo, Jingyi Zhang, Weiyao Li, Anhua Wang, Hongrui Lei, Zhonggui He, Ken‐ichiro Kamei, Jianzhao Niu, Lingyun Ma, Bingjun Sun   +16 more
wiley   +1 more source

Paclitaxel: new uses for an old drug

, 2014
Dongshan Zhang,1,2 Ruhao Yang,1 Shixuan Wang,2 Zheng Dong1,2 1Departments of Emergency Medicine and Nephrology, Second Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of China; 2Department of Cellular Biology and ...
Zhang D, Wang S, Dong Z, Yang R
core  

Nanomedicine‐driven innovations in postoperative cancer immunotherapy: Remodeling tumor microenvironment and precision delivery strategies

BMEMat, EarlyView.
Nanomedicine‐Driven Strategies for Suppressing Postoperative Tumor Recurrence. This schematic illustrates three pivotal nanomedical strategies that synergistically counteract recurrence by targeting residual disease and the immunosuppressive tumor microenvironment within the surgical cavity.
Lisong Pang, Zhuomin Wang, Zhenhua Jin, Ahmed H. Ghonaim, Hengcheng Zhang, Xinyu You, Jinzhuo Ning, Jiaqing Cao, Yang Liu   +8 more
wiley   +1 more source

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Nanoagonist‐mediated spatiotemporal reprogramming of macrophage phenotypes to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes the major molecular mechanisms governing TAM polarization and their coordinated interactions. It further highlights recent advances in nanoagonist‐based strategies that intervene in these pathways to reprogram TAMs, critically discussing their therapeutic potential, current limitations, and translational prospects.
Siqi Fang, Fengfeng Xiao, Ruie Chen, Cuixia Lu, Yi Ju, Mingqing Yuan, Yunlu Dai, Liewei Wen   +7 more
wiley   +1 more source

Synthesis of Paclitaxel Analogs

, 2010
Paclitaxel is one of the most successful anti-cancer drugs, particularly in the treatment of breast cancer and ovarian cancer. For the investigation of the interaction between paclitaxel and MD-2 protein, and development of new antagonists for ...
Xu, Zhibing
core  

Trans‐Patch Retrograde Re‐Entry During Hybrid Revascularization of an External Iliac Artery Chronic Total Occlusion: A Technical Note and Review of Re‐Entry Strategies

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Failure of true‐lumen re‐entry after subintimal wire passage is a well‐recognized limitation of endovascular treatment for external iliac artery (EIA) chronic total occlusions (CTO). We report a 73‐year‐old woman with severe limb ischemia and a prior failed endovascular attempt who underwent hybrid left common femoral artery (CFA ...
Bibhas Amatya, Dipankar Mukherjee
wiley   +1 more source

Comparison of the Clinical Effects of Paclitaxel and Paclitaxel plus Oxaliplatin as the Second-line Treatment of Advanced Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2009
Background and objective Second-line chemotherapy with taxanes for the patients with non-small cell lung cancer (NSCLC), who had disease recurrence or failure in previously treated with platinum-based chemotherapy, has been shown to be effective. Besides
Tianqing CHU, Hao LIN, Jie SHEN, Runbo ZHONG, Baohui HAN   +4 more
doaj  

One‐Year Clinical Outcomes of Paclitaxel‐Coated Balloon Angioplasty in Patients With and Without Acute Coronary Syndrome: The ALLIANCE Registry

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Real‐world data after percutaneous coronary intervention (PCI) using drug‐coated balloons (DCBs) in acute coronary syndrome (ACS) are limited. Aims We compared 1‐year clinical outcomes after PCI with paclitaxel DCBs between the ACS and non‐ACS patients.
Takashi Muramatsu, Kengo Tanabe, Kazushige Kadota, Yutaka Tadano, Kenji Ando, Shigeru Nakamura, Takashi Ashikaga, Yoshihisa Kinoshita, Nehiro Kuriyama, Yuko Ohnishi, Toru Kataoka, Koji Nishida, Raisuke Iijima, Masatsugu Nozoe, Kunio Morishige, Takefumi Takahashi, Yoshitaka Murakami, Ken Kozuma, Masato Nakamura   +18 more
wiley   +1 more source